Clinical trial
Tiotropium / Respimat One Year Study in COPD.
NCT00387088 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00387088 |
|---|---|
| Title | Tiotropium / Respimat One Year Study in COPD. |
| Official title | Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Device, Drug |
| Interventions | Respimat, Tiotropium |
| Enrollment | 3,991 |
| Start date | Sep 1, 2006 |
| Primary completion | Jan 1, 2009 |
| First posted | Oct 12, 2006 |
| Last update posted | May 16, 2014 |
| Countries | Australia, Brazil, Canada, China, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India and 19 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: